Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MiST: Targeted Therapies for Relapsed Malignant Mesothelioma
NCT03654833Phase 2Completed
- Sponsor
- University of Leicester
- Start
- Jan 2019
- Primary completion
- Feb 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of rucaparib, abemaciclib, pembrolizumab, bemcentinib, atezolizumab and 3 more in malignant mesothelioma (5 arms), sponsored by University of Leicester. Primary endpoint: Disease Control Rate at 12 weeks. Started Jan 2019; status: completed.
02
Drugs
03
Conditions
malignant mesothelioma
Beyond the preview
Go deeper on NCT03654833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03654833.